Housing these resources on LabXchange.org extends the Amgen Foundation’s ability to support any learner interested in scientific research from anywhere around the world.

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

Salveen Richter has given his Buy rating due to a combination of factors that highlight Amgen’s potential growth prospects. A critical focus is on the upcoming Phase 2 obesity data for MariTide ...

Amgen has won FDA approval for a stronger label ... chief scientific and medical officer at the National Psoriasis Foundation in the US. "Plaque psoriasis often affects patients more severely ...

Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN ... parallel-group trial will be presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association ...